This review determined the efficacy of peri-operative intranasal mupirocin for the prevention of surgical-site infection (SSI) according to type of surgical procedure. The authors concluded that peri-operative intranasal mupirocin appeared to reduce the incidence of SSI in non-general surgery, but had no apparent effect in general surgery. Given the limited evidence base and small number of randomised controlled trials, the authors' conclusion may be overstated.
Data extraction
Two reviewers independently extracted the data from the primary studies using a standardised form; any discrepancies were resolved through discussion, or by a third reviewer. Relative risks (RRs) and their 95% confidence intervals (CIs) were calculated for SSI. Where reported, data from intention-to-treat analysis were extracted.
Methods of synthesis
How were the studies combined? The studies were combined in a meta-analysis using a random-effects model. Efficacy estimates were reported as summary RRs with 95% CIs.
How were differences between studies investigated?
The studies were grouped by surgery (general or non-general, and cardiothoracic or orthopaedic) and by study design (RCT or non-randomised studies). The authors reported that statistical heterogeneity was assessed, but did not provide any further details.
Results of the review
Seven studies (n=11,088) were included in the review: 3 randomised controlled trials (RCTs; n=4,873) and 4 beforeand-after studies (n=6,215).
The 3 RCTs were given a research design rating of I; internal validity was rated as 'good' in 2 RCTs and "fair" in the other. The 4 non-randomised studies were given a research design rating of II and an internal validity rating of 'fair'.
General surgery.
In RCTs, the incidence of SSI ranged from 8.4 to 8.8% in the mupirocin group and from 6.9 to 8.3% in the control group; in the single non-randomised study, the incidence was 11.3% in the mupirocin group and 18.0% in the control group. No statistically significant difference in infection rate was found between mupirocin and the control group for RCTs (RR 1.04, 95% CI: 0.81, 1.33; 2 studies) or non-randomised studies (RR 0.63, 95% CI: 0.35, 1.14; 1 study). No statistically significant heterogeneity was found.
Non-general surgery.
In RCTs, the incidence of SSI ranged from 3.8 to 7.0% in the mupirocin group and from 4.7 to 8.8% in the control group; in non-randomised studies, SSI incidence ranged from 0.9 to 2.8% (mupirocin) and from 2.7 to 7.3% (control), respectively. When only RCTs were analysed, mupirocin use reduced infection (RR 0.80, 95% CI: 0.58, 1.10; 2 studies), although this was not statistically significant. A statistically significant reduction in infection rate was shown when only non-randomised studies were analysed (RR 0.40, 95% CI: 0.29, 0.56; 3 studies) . No statistically significant heterogeneity was found.
When cardiothoracic surgery studies were analysed, mupirocin was found to reduce infection compared with controls in both RCTs (RR 0.69, 95% CI: 0.46, 1.03; 1 study) and non-randomised studies (RR 0.37, 95% CI: 0.25, 0.55; 2 studies), although the difference was not statistically significant in the former. No statistically significant heterogeneity was found.
When orthopaedic surgery studies were analysed, mupirocin was found to reduce infection compared with controls in both RCTs (RR 0.81, 95% CI: 0.38, 1.73; 1 study) and non-randomised studies (RR 0.50, 95% CI: 0.27, 0.92; 1 study), although the difference was not statistically significant in the former.
Resistance and adverse events.
